Implications of a biosignature study of the placebo response in major depressive disorder

JAMA Psychiatry

Volumn 72, Issue 11, 2015, Pages 1073-1074

  Fava, Maurizio ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARFENTANIL C 11; MU OPIATE RECEPTOR; PLACEBO; SODIUM CHLORIDE; TRACER; UNCLASSIFIED DRUG; FENTANYL; NARCOTIC ANALGESIC AGENT; SEROTONIN UPTAKE INHIBITOR;

CROSSOVER PROCEDURE; EDITORIAL; HUMAN; MAJOR DEPRESSION; NEUROCHEMISTRY; NEUROIMAGING; NEUROTRANSMISSION; OUTCOME ASSESSMENT; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; METABOLISM; NUCLEUS ACCUMBENS; PROCEDURES;

ANALGESICS, OPIOID; DEPRESSIVE DISORDER, MAJOR; FEMALE; FENTANYL; HUMANS; MALE; NUCLEUS ACCUMBENS; PLACEBOS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID, MU; SEROTONIN UPTAKE INHIBITORS;

EID: 84946551136     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.1727     Document Type: Editorial

References (7)

1. Peciña M, Bohnert ASB, Sikora M, et al. Association between placebo-activated neural systems and antidepressant responses: Neurochemistry of placebo effects in major depression [published online September 30, 2015]. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2015.1335.
2. BrownWA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994;10 (4): 265-269.
3. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, FavaM. Open-label placebo for major depressive disorder: A pilot randomized controlled trial. Psychother Psychosom. 2012;81(5): 312-314.
4. Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry. 2013;3: E282. doi: 10.1038/tp.2013.43.
5. FavaM. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8): 649-659.
6. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? ameta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1): 34-40.
7. FavaM, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3): 115-127.